MustGrow Announces Record Q1-2025 Results: $3.8 Million Revenue, 14.3% Gross Profit Margin, $4.4 Million in Cash and Inventory
Register/View Here: https://us02web.zoom.us/webinar/register/6217478678603/WN_h8uMVWINQsmS3HWF8K59WgPlease join/register at least 5 minutes prior to the call.Questions emailed to info@mustgrow.ca will be addressed during the Q&A portion of the webcast.Saskatoon, Saskatchewan--(Newsfile Corp. - May 27, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MG
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-05-27 5:00 PM EDT | MustGrow Biologics Corp.
Awakn Life Sciences Announces Completion of Arrangement and Sale to Solvonis Therapeutics plc
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), is pleased to announce, further to its press releases dated February 27, 2025, April 11, 2025 and April 23, 2025, that Solvonis Therapeutics plc (LSE: SVNS) ("Solvonis")...
Technology, Biotechnology, Health
2025-05-27 12:05 PM EDT | Awakn Life Sciences Corp.
Telo Genomics Receives New Client Tier under Intellectual Property Ontario (IPON)
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, is pleased to announce that it has entered a new client agreement with...
2025-05-27 8:30 AM EDT | Telo Genomics Corp.
Sona Successfully Completes FDA-Required Toxicity Study
Halifax, Nova Scotia--(Newsfile Corp. - May 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce positive results from a required preclinical safety study evaluating for toxicity issues when animals are injected with its proprietary gold nanorods, conducted by CBSET, Inc. Donald Hodges,...
2025-05-27 8:27 AM EDT | Sona Nanotech Inc.
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial
New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for unmet mental health needs, today announced the finalization of its service agreement with Southern Star Research Pty Ltd ("Southern Star Research"), an award-winning,...
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-05-27 7:30 AM EDT | Psyence Biomedical Ltd.
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will...
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-05-27 7:27 AM EDT | Cardiol Therapeutics Inc.
Aires Announces Record First Quarter 2025 Revenue of $5.38 Million & 164% YoY Sales Growth
Gross Profit increased 184% YoYGross Margin increased 500 basis points to 65%2025 Guidance maintained: Sales of $28M to $32M, adjusted EBITDA of -$2M loss to $2M profitToronto, Ontario--(Newsfile Corp. - May 26, 2025) - American Aires Inc. (CSE: WiFi) (OTCQB: AAIRF) ("Aires" or the "Company"), a pioneer in advanced technology...
2025-05-26 4:30 PM EDT | American Aires Inc.
PreveCeutical Welcomes Stephen Glover as Corporate Advisor
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that Steve Glover has been appointed as...
Biotechnology, Pharmaceuticals, Health
2025-05-26 7:00 AM EDT | PreveCeutical Medical Inc.
Sharp Therapeutics Corp. Reports First Quarter 2025 Results
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 22, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces the release of its condensed interim consolidated financial statements for the three months ended March 31,...
2025-05-22 5:45 PM EDT | Sharp Therapeutics Corp.
PreveCeutical Closes Final Tranche of Up-Sized Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, following its news releases dated April 2, 2025, April 14, 2025, and April 28, 2025, it has successfully closed the final tranche ("Final Tranche") of...
Biotechnology, Pharmaceuticals, Health
2025-05-22 2:25 PM EDT | PreveCeutical Medical Inc.
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Philadelphia, Pennsylvania--(Newsfile Corp. - May 22, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that it has received study may proceed approval from the UAE DOH to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat BCC of the skin. The study is...
Banking/Financial Services, Biotechnology, Investment Banking, Health
2025-05-22 7:30 AM EDT | Medicus Pharma Ltd.
BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound
Rehovot, Israel--(Newsfile Corp. - May 21, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived...
Biotechnology, Pharmaceuticals, Health
2025-05-21 8:30 AM EDT | BioHarvest Sciences Inc.
NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that topline results from the chronic cohort of the ongoing Phase 1b/2a study of NVG-291 will be presented as an oral presentation at...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-21 7:30 AM EDT | NervGen Pharma Corp.
Bloom Burton & Co. Inc. Announces Exercise of Satellos Bioscience Inc. Warrants
Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Bloom Burton & Co. Inc. (Bloom Burton) announces that, today, it exercised 3,200,000 common share purchase warrants (Warrants) of Satellos Bioscience Inc. (Corporation) at $0.50 per share for aggregate consideration of $1,600,000, and the remaining 3,360,474 unexercised Warrants expired. This resulted in...
Technology, Biotechnology, Investment Banking, Health
2025-05-20 7:01 PM EDT | Bloom Burton & Co. Inc.
FDA-Zulassungsverfahren von Izotropic genehmigt - Unternehmen gibt Update
- Die Übereinstimmung mit den Vorgaben der FDA wurde bestätigt. Der Weg zu der wichtigen klinischen Studie in den USA ist somit frei -- 150-seitiger strategischer Geschäftsplan und genaue Finanzmodelle fertiggestellt -- Kontaktaufnahme mit Investoren zur Finanzierung der klinischen Durchführung und des Markteintritts im Gange -Vancouver, British Col
2025-05-20 3:48 PM EDT | Izotropic Corporation
Hemostemix Presents at TERMIS 2025, Freiburg, Germany
Freiburg, Germany--(Newsfile Corp. - May 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III clinical-stage biotechnology company developing autologous stem cell therapies for cardiovascular diseases, is presenting its groundbreaking clinical trial results and regenerative medicine innovations today at the Tissue Engineering and Regenerative Medicine International Society...
Biotechnology, Pharmaceuticals, Health
2025-05-20 9:00 AM EDT | Hemostemix Inc.
BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology
Vancouver, British Columbia--(Newsfile Corp. - May 20, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leader in developing liquid biopsy tests for early cancer detection, today announced the publication of a significant study exploring an artificial intelligence (AI) approach using novel graph neural networks (GNNs)...
Technology, Biotechnology, Healthcare and Hospitals
2025-05-20 8:30 AM EDT | BioMark Diagnostics, Inc.
Theralase Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various...
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-05-20 7:00 AM EDT | Theralase Technologies Inc.
Impact Fusion's Scientific Team Proposes Solution to the New World Screwworm Fly Impending Crisis
Napoleonville, Louisiana--(Newsfile Corp. - May 19, 2025) - Impact Fusion (OTC Pink: IFUS) As widely reported in the media and noted by concerned lawmakers, the USA is facing a serious infestation of the New World Screwworm Fly. This infestation could wreak havoc on the American beef cattle and dairy industries,...
2025-05-19 9:15 AM EDT | Impact Fusion International Inc.
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
Marlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-19 7:45 AM EDT | Phio Pharmaceuticals Corp.